Broadridge Financial Solutions, VeriFone Systems, Gilead Sciences, Johnson &
Johnson and Forest Laboratories highlighted as Zacks Bull and Bear of the Day
CHICAGO, Jan. 3, 2014
CHICAGO, Jan. 3, 2014 /PRNewswire/ --Zacks Equity Research highlights
Broadridge Financial Solutions (NYSE:BR-Free Report) as the Bull of the Day
and VeriFone Systems (NYSE:PAY-Free Report)as the Bear of the Day. In
addition, Zacks Equity Research provides analysis ontheGilead Sciences, Inc.
(Nasdaq:GILD-Free Report), Johnson & Johnson (NYSE:JNJ-Free Report) and Forest
Laboratories Inc. (NYSE:FRX-Free Report).
Here is a synopsis of all five stocks:
Bull of the Day:
Broadridge Financial Solutions (NYSE:BR-Free Report) is a provider of
technology solutions including investor communications, securities processing
and operations to banks, broker-dealers, mutual funds, and corporate issuers
It is the former Brokerage Services division of ADP and was spun-off from ADP
in 2007. The company has seen a compounded annual fee growth of 6% since it
BR processes 85% of all outstanding shares voted in the US and 72% of shares
voted outside of the US.
Broadridge reported financial results for the first quarter of its fiscal year
2014 on November 7, 2013. Total Revenues increased 10% to $545 million from
$496 million, primarily due to growth in net new business and by internal
Non-GAAP Diluted earnings increased 117% to $0.39 per share, substantially
ahead of the Zacks Consensus Estimate of $0.20 per share.
The management reaffirmed their full year guidance provided in August
2013--total revenue growth in the range of 2% to 4% and diluted earnings per
share in the range of $2.00 to $2.10.
After excellent results and reaffirmation of guidance, analysts have increased
their estimates for BR.
Zacks Consensus Estimate for the current and next fiscal year are now at $2.29
per share and $2.47 per share respectively, up from $2.06 per share and $2.26
per share, 60 days ago. Rising estimates sent BR to Zacks Rank # 1 (Strong
Buy) on November 14, 2013.
Bear of the Day:
VeriFone Systems (NYSE:PAY-Free Report) is a provider of technology for
electronic payment transactions and value-added services at the point of sale.
Its customers are primarily global financial institutions, payment processors,
petroleum companies, large retailers, government organizations and healthcare
companies, as well as independent sales organizations.
PAY reported the financial results for Q4 of the fiscal year ended October 31,
2013 on December 17, 2013. Net income for the quarter came in at $0.27 per
share, compared to $0.76 per share a year ago.After including stock based
compensation, the earnings were $0.13 per share, substantially short of the
Zacks Consensus Estimate of $0.18 per share.
Gross margin contracted 310 basis points from the previous-year quarter and
operating profit declined 70.4% mainly due to 11.5% year-over-year decline in
revenues and 28.1% increase in operating expenses.
The management expects non-GAAP revenues to be in the range of $425.0
million–$430.0 million for the first quarter of fiscal 2014, almost unchanged
from $429.0 million reported in the year-ago quarter.
Management expects first-quarter non-GAAP earnings to be $0.26 cents per
share, down from $0.40 per share in the year-ago quarter.
Bullish on Gilead
Gilead Sciences, Inc. (Nasdaq:GILD-Free Report) had a very successful 2013
driven by its strong product portfolio. The biopharmaceutical company ended
the year on a high with its blockbuster hopeful, Sovaldi, gaining U.S.
approval for treating patients suffering from chronic hepatitis C virus (HCV).
Sovaldi, with its high cure rates, a short treatment period and
reduction/elimination of the need for interferon injections, has the potential
to change the treatment paradigm in the HCV space. The approval has been
highly welcomed by HCV patients, many of whom have postponed their treatments
waiting for a better therapy like Sovaldi to gain approval. We expect uptake
in Sovaldi sales to be rapid, given its broad label and the pent-up demand for
new HCV therapies.
The U.S. approval for Sovaldi comes a few weeks after the clearance of Johnson
& Johnson's (NYSE:JNJ-Free Report) Olysio in combination with peg-IFN and
ribavirin for treating chronic HCV patients.
The European approval of Sovaldi is also on track with the European Medicines
Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)
recommending its approval in the EU in Nov 2013. The positive opinion by the
CHMP will be reviewed by the European Commission, which will issue final
opinion on whether to approve the HCV candidate in the EU.
Other newly launched drugs like HIV therapies Complera/Eviplera (launched in
2011) and Stribild (launched in 2012) also performed very well during 2013.
These drugs are expected to continue their strong performance in 2014 as well.
In Dec 2013, Complera/Eviplera's label was expanded. Complera can now replace
the existing antiretroviral treatment regimen in HIV infected adults. This
should boost the sales potential of the drug further. The European approval of
HIV drug Vitekta (elvitegravir) in Nov 2013 is another positive for Gilead.
Apart from the strong product portfolio, Gilead boasts of a robust pipeline.
One of the most interesting candidates at Gilead is idelalisib (formerly
GS-1101). The candidate, added to Gilead's pipeline through its acquisition of
Calistoga Pharmaceuticals in 2011, is being developed for multiple
At the annual meeting of the American Society of Hematology (ASH) in Dec 2013,
Gilead presented encouraging data on the candidate from a phase II study
(101-09: n=125) in the indolent non-Hodgkin's lymphoma (iNHL) indication, for
which Gilead is seeking U.S. approval. Gilead also intends to seek approval
for idelalisib in the chronic lymphocytic leukemia (CLL) indication and is in
discussions with the FDA regarding the same. Idelalisib is under review in the
EU in the CLL as well as iNHL indications. With the acceptance of Gilead's
request for accelerated assessment by the European Medicines Agency's (EMA)
Committee for Medicinal Products for Human Use (CHMP), idelalisib is expected
to be available in the EU in the latter half of 2014 (assuming approval).
Idelalisib on approval will augment Gilead's top line further. Another
promising candidate in Gilead's pipeline is GS-9973. Encouraging interim data
on the candidate from a phase II study was also presented at the ASH in
patients with relapsed or refractory CLL or NHL. The successful development
and subsequent commercialization of the pipeline candidates would boost
Gilead's top line further.
In view of the above positives, we expect the company to perform well in 2014
as well. Forest Laboratories Inc. (NYSE:FRX-Free Report) carries a Zacks Rank
#1 (Strong Buy).
Get today's Zacks #1 Stock of the Day with your free subscription to Profit
from the Pros newsletter:
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Click here to subscribe to this
free newsletter today.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Get the full Report on BR - FREE
Get the full Report on PAY - FREE
Get the full Report on GILD - FREE
Get the full Report on JNJ - FREE
Get the full Report on FRX - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such
Zacks Investment Research
800-767-3771 ext. 9339
Zacks.com provides investment resources and informs you of these resources,
which you may choose to use in making your own investment decisions. Zacks is
providing information on this resource to you subject to the Zacks "Terms and
Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.